Analytical utility assessment of myeloid NGS gene panel testing; a single site experience

Summary

In this presentation Dr. McCready will compare a hybridisation-based NGS panel versus single analyte and amplicon-based NGS assays for somatic mutation testing in myeloid malignancies, from her experience with OGT’s SureSeq myPanel™ Custom Myeloid - 49 gene plus panel.

Speaker information

Dr. Elizabeth McCready, PhD, FCCMG

• Head of Molecular Cytogenetics, Hamilton Regional Laboratory Medicine Program, Ontario, Canada
• Associate Professor, McMaster University, Ontario, Canada

Dr. McCready’s research activities are largely translational in nature, with particular interest in application of molecular cytogenetic techniques to characterise clinically relevant genetic variants that contribute to developmental disorders and cancer.

View Dr. Elizabeth McCready's profile on LinkedIn

Recent publications from the speaker

1. Genetic and metabolic investigations for neurodevelopmental disorders: position statement of the Canadian College of Medical Geneticists (CCMG)
2. Further characterization of the 9q31 microdeletion phenotype; delineation of a common region of overlap containing ZNF462
3. A retrospective cohort study of donor cell leukemia

Disclaimer

This presentation is intended for educational purposes only and does not replace independent professional judgment. Statements of fact and opinions expressed are those of the presenters individually and, unless expressly stated to the contrary, are not the opinion or position of the Oxford Gene Technology Group (OGT). OGT does not endorse or approve, and assumes no responsibility for, the content, accuracy or completeness of the information presented.

SureSeq™: For Research Use Only; Not for Use in Diagnostic Procedures.